论文部分内容阅读
一、MDL17043的动物实验研究 MDL17043(1,3 dihydro 4-methy-5〔4-(methylthi0)一benzoyl〕-2H-imi dazol-2-one),一种非儿茶酚胺、非糖甙类的新强心剂,目前临床正试用于治疗难治性心力衰竭。 Dage和Roebel(1982)就该药物作用进行了动物实验研究,发现在麻醉状态下但神志清醒的狗,静脉注射MDL17043可使其心脏产生正性肌力作用,并伴有轻度心率加快和短暂血压降低,但无心肌氧耗增加。同时,Dage还发现该药的心缩力增强效应,不引起心搏量增加。考虑为静脉容量血管扩张,回心血量下降,心室容积减少所致。此外MDL17043在活体狗心-肺模型的心功能
First, the animal experiments MDL17043 MDL17043 (1,3 dihydro 4-methy-5 [4- (methylthi0) a benzoyl] -2H-imi dazol-2-one, a non-catecholamines, non-glycosides of the new cardiac , Clinical trial is currently being used to treat refractory heart failure. Dage and Roebel (1982) conducted an animal study of the drug’s effects and found that anesthetized but conscious dogs, MDL17043 intravenous injection of the heart can produce positive inotropic effect, accompanied by mild heart rate and shortening Blood pressure, but no increase in myocardial oxygen consumption. At the same time, Dage also found that the drug’s cardiac contractility enhanced effect, does not cause increased stroke volume. Consider the vasodilatation of venous capacity, back to the blood volume decreased, decreased ventricular volume. In addition MDL17043 in the live dog heart-lung model of cardiac function